题目化疗联合抗病毒治疗成人T细胞白血病/淋巴瘤的临床研究.目的探讨化疗联合抗病毒治疗成人T细胞白血病/淋巴瘤的疗效及相关预后因素.方法将2018年1月至2021年1月收治的49例既往确诊或新诊断的成人T细胞白血病/淋巴瘤患者纳入研究。根据是否行抗病毒治疗将患者分为2组，化疗联合抗病毒治疗组27例，其中13例用重组人α-2b干扰素联合CHOP方案治疗，8例用齐多夫定联合CHOP方案化疗，6例采用CHOP方案联合干扰素加齐多夫定治疗；单纯化疗组22例，单用CHOP治疗。通过比较2组患者治疗前后症状、血常规、LDH、β2微球蛋白、Ki-67等指标变化，评估化疗联合抗病毒治疗ATLL的临床疗效，检测HTLV-1病毒拷贝数以评价抗病毒的效果，并进行相关预后因素分析.结果中位随访时间为14个月。与单纯化疗相比，经化疗联合抗病毒治疗患者肿瘤负荷较治疗前明显减轻，HTLV-1病毒拷贝数明显下降，白细胞数、LDH、β2-MG、Ki-67阳性率及HTLV-1病毒量等指标均明显降低（P＜0.05）；化疗联合抗病毒组总有效率(CR+PR)明显高于单纯化疗组(63.0% vs 31.8%, P=0.035)。化疗联合抗病毒组、单纯化疗组患者1年总生存率分别为(74.1±2.9)％和(40.9±2.1)％（P=0.021），1年无进展生存率分别为(51.9±3.3)％和(13.6±2.8)％（P=0.017）。多因素分析结果显示，HTLV-1病毒量及是否抗病毒治疗为影响患者远期疗效的独立危险因素（HR=7.518， 95%CI： 2.517-36.192, P=0.013; HR=5.617， 95%CI： 1.803-11.293， P=0.027）.结论ATLL化疗基础上加用抗病毒可提高其疗效，延长其无进展生存时间及总体生存时间，HTLV-1病毒量及是否抗病毒治疗可影响患者长期预后.

2022-09-01·Protein Expression and Purification4区 · 生物学

Solvent extraction of recombinant interferon alpha-2b from inclusion bodies and efficient refolding at high protein concentrations

4区 · 生物学

Article

作者: Mousavi, Seyed Babak ; Davarpanah, Seyed Javad

Interferon alpha-2b (IFNα-2b) is an essential cytokine widely used in hepatitis and cancer treatment. This paper presents a novel protocol for purification and efficient refolding of recombinant interferon alpha-2b (IFNα-2b) expressed as insoluble inclusion bodies in Escherichia coli. Purification of IFNα-2b from solubilized inclusion bodies was performed by solvent extraction using 2-butanol. Refolding conditions were optimized using the response surface method (RSM). Under optimized conditions, refolding yield of solvent-extracted IFNα-2b was 1.5 fold higher than refolding yield of unpurified IFNα-2b. High-concentration protein refolding was carried out by pulse-fed method, and refolding yield of 75% was achieved at a protein concentration of 300 μg ml^-1. Under optimized conditions, 259.16 mg of purified IFNα-2b with the biological activity of 2.4 × 10⁸ IU mg^-1 was achieved per liter of bacterial culture. The developed protocol provides an efficient production process of high-quality IFNα-2b suitable for research and pharmaceutical applications.

2021-06-01·International Journal of Infectious Diseases3区 · 医学

Efficacy and safety of interferon α-2b spray for herpangina in children: A randomized, controlled trial

3区 · 医学

ArticleOA

作者: Deng, Ji-Kui ; Luo, Ru-Ping ; Chen, Bi-Quan ; Hao, Jian-Hua ; Yu, Hui ; Ye, Ying-Zi ; Lei, Min ; Gan, Lu ; Long, Yuan-Yuan ; Chen, Yan ; Lin, Ai-Wei ; Liao, Yi-Nan ; Nong, Guang-Min ; Wang, Shao-Ning ; Yan, Wei-Li ; Dou, Ya-Lan ; Zhou, Li ; Yang, Zhi

OBJECTIVESThe treatment of acute herpangina is inconsistent. We aim to evaluate the effectiveness and safety of interferon α-2b spray versus Ribavirin for this disease.METHODSA randomized, controlled trial was conducted in eight hospitals in China between 2016 and 2018. 668 patients (1-7 years old) were randomized into an experimental group (treated with Interferon α-2b spray) or control group (received Ribavirin Aerosol). Body temperature returning to normal within 72 h and remaining so for 24 h was the primary outcome; release of oral herpes and adverse events were the secondary outcomes.RESULTS(1) The average age of onset was 2.5 years old. (2) After 72 h treatment, body temperature of 98.5% patients in experimental group and 94.3% in control group returned to normal and remained so for 24 h (P = 0.004). The differences were greater at 48 h treatment (95.2% vs. 85.9%, P < 0.001) and at 24 h (77.5% vs. 66.5%, P = 0.001). (3) The rate of improved oral herpes in the experimental group was higher than that in control group (46.7% vs.37.1%, P = 0.011). No adverse reaction occurred.CONCLUSIONSLocal application of recombinant interferon α-2b spray showed better efficacy for acute herpangina in children. It was safe for use.

100 项与干扰素α-2b生物类似药(Intas Biopharmaceuticals Ltd.) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	L03AB05	-

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
乙型肝炎	印度	Intas Biopharmaceuticals Ltd.	2007-01-01
丙型肝炎	印度	Intas Biopharmaceuticals Ltd.	2007-01-01
肿瘤	印度	Intas Biopharmaceuticals Ltd.	2007-01-01